News

The Margin: Usain Bolt is missing millions from his investment portfolio, his manager says

0

Did someone pull a fast one on Usain Bolt?

The legendary Brazilian sprinter is missing millions of dollars from his investment portfolio at Stocks and Securities Limited (SSL), according to his manager, and an investigation has been launched to sort out what happened.

Bolt’s representative, Nugent Walker, told Jamaican media outlet The Gleaner this week that the country’s Financial Investigations Division and Financial Services Commission is probing SSL. “All the relevant steps have been taken to come to the bottom of this,” Walker said.

Bolt, an eight-time Olympic gold medalist, reportedly first noticed inconsistencies with his SSL accounts this past week.

“He’s been with this entity over 10 years … His entire portfolio is being reviewed,” Walker said, adding that the case is ongoing.

According to the same Gleaner report, a now-former SSL employee has been implicated in a fraud scheme at the company, and may have been linked to the reported issues surrounding Bolt’s investments. Attorney Tamika Harris, who is representing the former employee, said that her client has been talking with legal representatives of SSL for two weeks.

Representatives for Bolt and SSL did not respond to MarketWatch’s requests for comment on this story.

Bolt is widely considered the “fastest man alive” and one of the greatest athletes of all time. He holds world records in the 100-meter, 200-meter and 4×100-meter relay. He retired from running track and field professionally in 2017.

See also: Tom Brady’s FTX shares were once worth $45 million. Will he lose it all?

Bolt is also seen as a savvy businessman. He has lucrative sponsorships deals with companies such as Puma, Hublot and Gatorade; owns an eSports team; and has a non-fungible token (NFT) deal with Tom Brady’s Autograph company. Bolt made $31 million in 2018 (the year after he retired) and $30 million of that fortune came via his off-the-track endeavors, according to Forbes.

: Drug companies plan to raise prices on vital medicines to fund R&D, but they already spend more on shareholder returns than research

Previous article

: ‘Poker move’ or wake-up call? Wall Street weighs in on Tesla’s price cuts.

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in News